文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

单剂帕博利珠单抗诱发的糖尿病酮症酸中毒

Diabetic ketoacidosis induced by a single dose of pembrolizumab.
PubMed 文献 · Am J Emerg Med · 2018-10-21
一句话结论无糖尿病史女性在接受单剂帕博利珠单抗后3周内以糖尿病酮症酸中毒就诊,提示免疫检查点抑制剂可诱发暴发性1型糖尿病,作者认为需密切监测。

本文报告一例无已知糖尿病史的成年女性,在仅接受单剂帕博利珠单抗治疗、且既往未接触过免疫治疗的情况下,于3周内因糖尿病酮症酸中毒到急诊科就诊,表现为 abrupt adult-onset 1型糖尿病。帕博利珠单抗靶向PD-1受体,阻断其与PD-L1及PD-L2的相互作用,临床试验中其诱发免疫介导的1型糖尿病非常罕见(0.1%)。作者指出这是短期暴露于免疫检查点抑制剂后即可出现不良副作用的例证,认为对接受免疫检查点抑制剂的患者需密切监测,以早期诊断和处理即将发生且可能危及生命的并发症。

要点

  • 临床试验中帕博利珠单抗诱发免疫介导的1型糖尿病非常罕见,发生率为0.1%。
  • 本例无糖尿病史成年女性在仅接受单剂帕博利珠单抗后3周内以糖尿病酮症酸中毒到急诊科就诊。
  • 该患者既往未接触过免疫治疗,提示单次短期暴露即可出现暴发性成年起病1型糖尿病。
  • 作者认为,对接受免疫检查点抑制剂的患者需密切监测,以早期诊断和处理可能危及生命的并发症。

适用人群与场景

  • 接受免疫检查点抑制剂(如帕博利珠单抗)治疗恶性肿瘤的患者,包括既往无糖尿病史者。
  • 急诊科场景:接受帕博利珠单抗后短时间内以糖尿病酮症酸中毒状态就诊的成年患者。

红旗征与不能漏的情况

  • 接受帕博利珠单抗后短期内出现糖尿病酮症酸中毒状态,需考虑免疫检查点抑制剂诱发的1型糖尿病。

研究设计与关键结果

  • 病例报告:一例无已知糖尿病史的成年女性,在仅接受单剂帕博利珠单抗治疗、且既往未接触免疫治疗后3周内,以糖尿病酮症酸中毒状态到急诊科就诊,诊断为暴发性成年起病1型糖尿病。
  • 临床试验中免疫检查点抑制剂(如帕博利珠单抗)诱发免疫介导的1型糖尿病非常罕见,发生率为0.1%。

证据类型、等级与局限

  • 证据类型:病例报告。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,对接受免疫检查点抑制剂的患者需密切监测,以早期诊断和处理即将发生且可能危及生命的并发症。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Immune checkpoint inhibitors are a new class of anticancer drugs recently approved by the US Food and Drug Administration (FDA) for the treatment of various malignancies. Pembrolizumab is an immune checkpoint inhibitor that targets the programmed cell death protein-1 (PD-1) receptor and blocks its interaction with programmed cell death ligand-1 (PD-L1) and programmed cell death ligand-2 (PD-L2). Pembrolizumab was first approved by the FDA in 2014 for the treatment of advanced melanoma and is currently approved for use in non-small cell lung cancer and several other neoplasms. Immune checkpoint inhibitors such as pembrolizumab have been reported to induce immune-mediated side effects, including type 1 diabetes mellitus in very rare cases (0.1% in clinical trials). Here, we report the case of a woman with no known history of diabetes who presented to our emergency department in a state of diabetic ketoacidosis within 3 weeks of receiving only a single dose of pembrolizumab therapy, and without any previous exposure to immunotherapy. This case of abrupt adult-onset type 1 diabetes mellitus is an example of the undesirable side effects that can emerge after only a brief exposure to an immune checkpoint inhibitor. Close monitoring of patients receiving immune checkpoint inhibitors is warranted for the early diagnosis and management of imminent and potentially life-threatening complications.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Maamari J, Yeung SJ, Chaftari PS, et al. Diabetic ketoacidosis induced by a single dose of pembrolizumab. Am J Emerg Med. 2018. PMID: 30361152. doi:10.1016/j.ajem.2018.10.040

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。